Data gathered: November 27
Alternative Data for Immutep
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 92 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Google Trends | 6 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 772 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 6 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 8,902 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,000 | Sign up | Sign up | Sign up |
| Twitter Mentions | 6 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 173 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 49 | Sign up | Sign up | Sign up |
About Immutep
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism.
| Price | $1.99 |
| Target Price | Sign up |
| Volume | 67,610 |
| Market Cap | $303M |
| Year Range | $1.77 - $3.23 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Immutep: Potential Of Efti As New Standard Of Care For NSCLC PatientsNovember 14 - SeekingAlpha |
 |
Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung CancerNovember 13 - Yahoo |
 |
Immutep (ASX:IMM) shareholders have endured a 51% loss from investing in the stock three years agoNovember 6 - Yahoo |
Immutep’s Growth and Advancements Boost Market VisibilityOctober 29 - TipRanks |
|
|
Immutep Quarterly Activities Report Q1 FY25October 28 - Yahoo |
Immutep reports Q1 cash receipts from custmers $20,000October 28 - TipRanks |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 1.7M | 21M | -19M | -21M | -22M | |
| Q2 '24 | 1.7M | 21M | -19M | -21M | -22M | 0.000 |
| Q1 '24 | 0 | 0 | 0 | 0 | 0 | 0.000 |
| Q4 '23 | 2.1M | 1,000,000 | 1.1M | -21M | -22M | 0.000 |
| Q3 '23 | 1.8M | 920,000 | 900,000 | -19M | -19M | 0.000 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about Immutep (IMMP) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Immutep?
The Market Cap of Immutep is $303M.
What is the current stock price of Immutep?
Currently, the price of one share of Immutep stock is $1.99.
How can I analyze the IMMP stock price chart for investment decisions?
The IMMP stock price chart above provides a comprehensive visual representation of Immutep's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Immutep shares. Our platform offers an up-to-date IMMP stock price chart, along with technical data analysis and alternative data insights.
Does IMMP offer dividends to its shareholders?
As of our latest update, Immutep (IMMP) does not offer dividends to its shareholders. Investors interested in Immutep should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Immutep?
Some of the similar stocks of Immutep are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.